Literature DB >> 8101470

Polymerase chain reaction-based restriction fragment length polymorphism analysis of the short arm of chromosome 3 in primary head and neck squamous carcinoma.

A K el-Naggar1, M S Lee, G Wang, M A Luna, H Goepfert, J G Batsakis.   

Abstract

BACKGROUND: Deletion or loss of heterozygosity (LOH) at the polymorphic loci on the short arm of chromosome 3 has been reported in a large number of renal cell, small cell lung, non-small cell lung, and cervical carcinomas, suggesting the presence of one or more putative tumor suppressor genes at chromosome 3p. Similar studies in primary head and neck carcinoma are lacking.
METHODS: To investigate the possibility of chromosome 3p deletions, the authors applied a polymerase chain reaction (PCR)-based, restriction fragment length polymorphism analysis, in conjunction with conventional Southern blot techniques, to DNA samples of matched normal mucosa and head and neck squamous cell carcinomas from 18 patients. The authors also assessed the merit of the PCR-based assay as a rapid screening tool, particularly in assaying limited tissue samples.
RESULTS: Constitutional heterozygosity at the polymorphic loci varied in the 18 normal samples that the authors studied: 12 at the D3F15S2 locus (on telomeric 3p21), 7 at the D3S32 locus (on centromeric 3p21), and 9 at the THRB locus (on 3p24). In 18 matched carcinoma specimens, LOH (deletion) was observed at D3S32 in 0 of 7, at D3F15S2 in 9 of 12 (75%), and at THRB in 3 of 9 cases (33%).
CONCLUSIONS: The results of the PCR-based assay and Southern blotting were completely concordant in all specimens the authors studied. This study indicates that deletion at 3p is a frequent abnormality in primary head and neck carcinoma and that the most common deletion region is telomeric to D3S32. The authors also observed an apparent correlation among poor histologic differentiation, DNA aneuploidy, and 3p deletions. Most poorly and moderately differentiated and aneuploid carcinomas manifested the 3p deletion. Therefore, the authors suggest an association between deletion at 3p and aggressive biologic behavior.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101470     DOI: 10.1002/1097-0142(19930801)72:3<881::aid-cncr2820720337>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Microsatellite alteration at chromosome 3p loci in neuroendocrine and non-neuroendocrine lung tumors. Histogenetic and clinical relevance.

Authors:  K Hurr; B Kemp; S A Silver; A K el-Naggar
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

Review 2.  Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis.

Authors:  V A Papadimitrakopoulou; D M Shin; W K Hong
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

3.  The role of chromosomal aberrations in premalignant and malignant lesions in head and neck squamous cell carcinoma.

Authors:  Kamal-Eldin Ahmed Abou-Elhamd; Tito Naeem Habib
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-08-16       Impact factor: 2.503

4.  Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors.

Authors:  He-Yu Zhang; Kandelaria M Rumilla; Long Jin; Nobuki Nakamura; Gail A Stilling; Katharina H Ruebel; Timothy J Hobday; Charles Erlichman; Lori A Erickson; Ricardo V Lloyd
Journal:  Endocrine       Date:  2006-12       Impact factor: 3.633

Review 5.  Oral field cancerization: an update on current concepts.

Authors:  Meenakshi Mohan; Nithya Jagannathan
Journal:  Oncol Rev       Date:  2014-06-30

6.  Frequent gene deletions in potentially malignant oral lesions.

Authors:  G Emilion; J D Langdon; P Speight; M Partridge
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

7.  The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer.

Authors:  M Partridge; G Emilion; S Pateromichelakis; R A'Hern; G Lee; E Phillips; J Langdon
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.